MERCK: INTERIM ANALYSIS OF A PHASE 3 TRIAL SHOWED CLESROVIMAB HAD COMPARABLE SAFETY PROFILE TO PALIVIZUMAB IN INFANTS & CHILDREN

Reuters · 10/17 22:00

Please log in to view news